Anti-CD3 mAb (Teplizumab) for Prevention of Diabetes in Relatives At Risk for Type 1 Diabetes Mellitus

This study is for:

About this study

Teplizumab has been shown to preserve pancreas function in people with recently-diagnosed T1D (link to Diabetes 62:3766–3774, 2013). This trial is testing whether Teplizumab prevents diabetes in people at very high risk of developing it.

This is a randomised controlled trial, meaning one half of the participants are randomly allocated to receive Teplizumab and the other half to placebo.

Participation involves a 14-day treatment phase of daily infusions followed by 3- to 6-monthly follow-up visits.

This trial is open to all Australian residents, with the treatment phase delivered in Melbourne.

For more information about this study

Gleevec

This study is no longer recruiting

GleeT1D is a clinical trial that is testing whether a cancer drug called imatinib improves pancreas function in recently-diagnosed T1D.

 

Sixty-seven participants were recruited in Australia and the US and preliminary results of the study can be found on the Gleevec website.

For more information about this study

The Type 1 Diabetes Prevention Trial or
Intranasal Insulin Trial (INIT II)

This study is no longer recruiting

The INIT II study is testing whether a nasal spray developed by Professor Len Harrison prevents high-risk people developing T1D.

From 2006 to 2014, 110 high-risk children and young adults from Australia, New Zealand and Germany were enrolled in the trial.

The treatment phase finished in 2014 and follow-up will continue until at least 2019. Preliminary results are expected in 2017.

For more information about this study